^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Capillary permeability modulator

    Related drugs:
    6ms
    BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, Lisata Therapeutics, Inc. | Trial completion date: Mar 2026 --> Mar 2030 | Trial primary completion date: Apr 2025 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • certepetide (LSTA1)
    6ms
    FORTIFIDE: Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Lisata Therapeutics, Inc. | Trial completion date: Apr 2025 --> Jan 2040 | Initiation date: Jan 2025 --> Jan 2030 | Trial primary completion date: Apr 2025 --> Jan 2035
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • certepetide (LSTA1)
    7ms
    FORTIFIDE: Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Lisata Therapeutics, Inc. | N=30 --> 0 | Trial completion date: Sep 2027 --> Apr 2025 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2027 --> Apr 2025
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • certepetide (LSTA1)
    7ms
    BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=67, Active, not recruiting, Lisata Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Apr 2025
    Enrollment closed • Trial primary completion date
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • certepetide (LSTA1)
    12ms
    CENDIFOX: CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, Anup Kasi | Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2 | Trial completion date: Sep 2025 --> Sep 2026 | Trial primary completion date: Sep 2023 --> Sep 2025
    Enrollment closed • Phase classification • Trial completion date • Trial primary completion date • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    5-fluorouracil • Vectibix (panitumumab) • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
    12ms
    BOLSTER: A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=80, Recruiting, Lisata Therapeutics, Inc. | Trial completion date: Dec 2025 --> Mar 2026 | Trial primary completion date: Dec 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Metastases
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • 5-fluorouracil • oxaliplatin • leucovorin calcium • certepetide (LSTA1)
    12ms
    FORTIFIDE: LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Lisata Therapeutics, Inc. | Trial completion date: Jun 2027 --> Sep 2027 | Initiation date: Dec 2024 --> Mar 2025 | Trial primary completion date: Jun 2027 --> Sep 2027
    Trial completion date • Trial initiation date • Trial primary completion date • Metastases
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
    1year
    FORTIFIDE: LSTA1 Phase 1b/2a Continuous Infusion Trial in mPDAC (clinicaltrials.gov)
    P1/2, N=30, Recruiting, Lisata Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
    1year
    FORTIFIDE: LSTA1 Phase 1b/2a Continuous Infusion Trial in MPDAC (clinicaltrials.gov)
    P1/2, N=30, Not yet recruiting, Lisata Therapeutics, Inc.
    New P1/2 trial • Metastases
    |
    gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • certepetide (LSTA1)
    over1year
    CEND-1 Injection (QLC12102) in Patients With Advanced Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P1/2, N=50, Completed, Qilu Pharmaceutical Co., Ltd. | Recruiting --> Completed | Phase classification: P1b/2 --> P1/2 | Trial completion date: May 2023 --> Jun 2024 | Trial primary completion date: May 2023 --> Jun 2024
    Trial completion • Phase classification • Trial completion date • Trial primary completion date • Metastases
    |
    paclitaxel • certepetide (LSTA1)
    over1year
    CEND1-202: A Study of CEND-1 With Chemotherapy as First-Line Therapy in Patients With Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=120, Recruiting, Qilu Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    gemcitabine • albumin-bound paclitaxel • certepetide (LSTA1)
    over1year
    Intraperitoneal LSTA1 in CRS-HIPEC (clinicaltrials.gov)
    P1, N=0, Withdrawn, University of California, San Diego | N=21 --> 0 | Trial completion date: Dec 2029 --> Jun 2024 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2028 --> Jun 2024
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date • Surgery
    |
    certepetide (LSTA1)